Skip to main content

Translational strategies to develop clinically safe and effective immune cell engagers

24 Sep 2024
Translational Research
  • Ways to determine FiH dose for oncology trials with immune cell engaging multi-specific antibodies
  • Approaches for preclinical efficacy of combination therapies 
  • Have you worked on molecules which do not have an ideal in vivo efficacy/safety model? What are the additional hurdles to consider in such scenarios?
Industry Expert
Udaya Rangaswamy, Director Translational Biology - Rondo Therapeutics